Sexually Transmitted Disease Diagnostics Market by Disease Type (Bacterial Vaginosis, Candidal Vaginitis, Chlamydia Trachomatis/ Neisseria Gonorrhoeae), Diagnostic methods (Antigen Detection, Molecular Diagnostics, Serologic Testing), Device Type, End-Users - Global Forecast 2024-2030
The Sexually Transmitted Disease Diagnostics Market size was estimated at USD 106.53 billion in 2023 and expected to reach USD 112.56 billion in 2024, at a CAGR 5.97% to reach USD 159.97 billion by 2030.
Sexually transmitted disease diagnostics refers to the range of medical tests, physical examinations, and procedures used to identify infections transmitted through sexual contact. These diagnostics are crucial for the early detection, treatment, and prevention of sexually transmitted diseases, supporting public health efforts and individual well-being. The methodologies for Sexually transmitted disease (STD) diagnostics vary, including laboratory-based tests such as nucleic acid amplification tests, cultures, enzyme immunoassays (EIAs), and point-of-care tests that offer rapid results. The rising prevalence of STDs worldwide is a major contributor to the growth of diagnostics. This increase is attributed to changing sexual behaviors, lack of education and awareness regarding sexual health, and insufficient screening programs in certain regions. The need for effective diagnostic solutions is thus highlighted, prompting an uptick in demand for STD diagnostics. However, the social stigma associated with STDs remains a significant challenge for STD diagnostic providers. Companies are increasingly focusing on STD prevention and control as part of their public health initiatives. Moreover, the rapid progress in medical diagnostic technologies, including molecular diagnostics, Polymerase Chain Reaction (PCR) testing, and immunoassays, has significantly enhanced the accuracy, efficiency, and speed of STD testing. These technological advancements facilitate the early detection and treatment of STDs, further driving the growth of STD diagnostics.
Please Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. The rising prevalence of sexual diseases worldwide and the need for effective diagnostic solutions
- 5.1.1.2. Increasing implementation of worldwide screening to reduce the stigma associated with STD
- 5.1.2. Restraints
- 5.1.2.1. Lack of adequate awareness and education about STDs
- 5.1.3. Opportunities
- 5.1.3.1. Increased funding and public health campaigns for STD awareness and prevention
- 5.1.3.2. Innovations in next-generation sequencing and CRISPR-based diagnostics
- 5.1.4. Challenges
- 5.1.4.1. Stringent government regulations for drug approvals and complications arising from untreated infections
- 5.2. Market Segmentation Analysis
- 5.2.1. Disease Type: Advancements in next-generation sequencing and CRISPR-based diagnostics to cater varied STDs
- 5.2.2. End-Users: Increasing adoption of STD diagnostics in clinical and hospital settings to cater complicated STD cases
- 5.3. Market Disruption Analysis
- 5.4. Porter’s Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
- 5.5. Value Chain & Critical Path Analysis
- 5.6. Pricing Analysis
- 5.7. Technology Analysis
- 5.8. Patent Analysis
- 5.9. Trade Analysis
- 5.10. Regulatory Framework Analysis
- 6. Sexually Transmitted Disease Diagnostics Market, by Disease Type
- 6.1. Introduction
- 6.2. Bacterial Vaginosis
- 6.3. Candidal Vaginitis
- 6.4. Chlamydia Trachomatis/ Neisseria Gonorrhoeae
- 6.5. Genital Warts
- 6.6. Hepatitis B
- 6.7. HIV/AIDS
- 6.8. Mycoplasma Genitalium
- 6.9. Syphilis
- 6.10. Trichomoniasis
- 7. Sexually Transmitted Disease Diagnostics Market, by Diagnostic methods
- 7.1. Introduction
- 7.2. Antigen Detection
- 7.3. Molecular Diagnostics
- 7.4. Serologic Testing
- 8. Sexually Transmitted Disease Diagnostics Market, by Device Type
- 8.1. Introduction
- 8.2. Laboratory Devices
- 8.3. Point of Care Devices
- 9. Sexually Transmitted Disease Diagnostics Market, by End-Users
- 9.1. Introduction
- 9.2. Clinics
- 9.3. Diagnostic Laboratories
- 9.4. Hospitals
- 9.5. Public Health Agencies
- 9.6. Research Institutions
- 10. Americas Sexually Transmitted Disease Diagnostics Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Sexually Transmitted Disease Diagnostics Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Sexually Transmitted Disease Diagnostics Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. Market Share Analysis, 2023
- 13.2. FPNV Positioning Matrix, 2023
- 13.3. Competitive Scenario Analysis
- 13.3.1. British startup launches tampon that offers STI screening
- 13.3.2. BioPerfectus Launches New PCR Kits for Sexually Transmitted Diseases Diagnostic Solution
- 13.3.3. Mylab Launches rapid tests for sexually transmitted diseases
- 13.4. Strategy Analysis & Recommendation
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.2. Key Product Portfolio
- FIGURE 1. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
- FIGURE 2. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
- FIGURE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET DYNAMICS
- FIGURE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
- FIGURE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2023 VS 2030 (%)
- FIGURE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2023 VS 2030 (%)
- FIGURE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
- FIGURE 14. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
- FIGURE 24. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook